A new C 21 cyclopentenone derivative, Cipacyclonone (1), was isolated from the leaves of Cipadessa cinerascens. Its structure was elucidated on the basis of spectroscopic analysis, including extensive 1D-and 2D-NMR techniques. Compound 1 showed strong cytotoxicity activity against HL-60 and A-549 cell lines, with IC 50 values of 1.2 and 3.0 μM, respectively.
The genus Cipadessa (Meliaceae) comprises nine species of shrubs or small trees, which are mainly distributed in India and southwest China [1] . C. cinerascens (Pell.) Hand.-Mazz. is a medicinal plant widely distributed in the southwest of China [2, 3] . The folk medicine "Ya Luo Qing", derived from the leaves and roots of C. cinerascens, has been used for the treatment of dysentery, skin itch, malaria, and burns by the Tai nationality [4] . In our efforts for new natural products with significant bioactivity from medicinal plants, a C 21 cyclopentenone derivative, Cipacyclonone (1), along with six known compounds 13-labdene-8,15-diol (2) [5] , 2-hydroxyandrosta-1,4-diene-3,16-dione (3) [6] , cipadesin D (4), cipadesin E (5), cipadesin F (6) [7] , and cipadesin G (7) [8] , were isolated from the 95% EtOH extract of the aerial parts of C. cinerascens. Compounds 2 and 3 were reported from the title plant for the first time. and one methyl group (δ C 13.7). The gross structure of 1 was deduced from detailed analysis of the 1 H and 13 C NMR data (Table 1) , aided by 2D NMR experiments. The 1 H-1 H COSY and HSQC spectra of 1 revealed the existence of a long spin system from C-2 to C-21 (as shown in bold in Figure 1A ). The HMBC correlations from H-2, H-3 and H-5 to C-1 indicated the presence of a cyclopent-2-enone moiety. Thus, the planar structure of 1 was elucidated as shown. cofacial and arbitrarily defined as α-orientation. Cross peaks of H-12/H-13 and H-13/H-15 in the ROESY spectrum showed that these protons were located on the same side. Thus, the geometry of ∆ 12-13 and ∆ 14-15 double bonds was assigned as E-and Z-form, respectively. Moreover, the configuration of the ∆ 18-19 double bond was determined as E-form due to key ROE correlation between H-18 and H-19. Thus, the structure of 1 was established as shown.
The cytotoxicity assays showed that compound 1 had strong activity against the acute myelogenous leukemia (HL-60) cell line with an IC 50 value of 1.2 µM, and human lung cancer (A-549) cell line with an IC 50 value of 3.0 µM.
Experimental

General:
1 H and 13 C NMR, Bruker AM-400 spectrometer; 2D NMR, Bruker DRX-500 instrument; ESIMS and HRESIMS, VG ZABHS and Auto Spec-3000 spectrometers, respectively; Optical rotations, Perkin-Elmer model 241 polarimeter; IR, Bio-Rad FTS-135 spectrometer; CC was performed on silica gel (90-150 µm; Qingdao Marine Chemical Inc. Qingdao, China). Precoated silica gel GF 254 and HF 254 plates (Qingdao Marine Chemical Inc. Qingdao, China) were used for thin-layer chromatography (TLC). 
Extraction and isolation:
The air-dried powdered leaves (19.0 kg) were extracted 3 times (4, 3, and 3 h) with 95% ethanol (20 L × 3) at room temperature and concentrated in vacuo at 60ºC to give a residue (320 g). The residue was dispersed in water (4.0 L) and extracted with light petroleum and then EtOAc to give the EtOAcsoluble fraction (E-Fraction, 500 g). The E-Fraction was processed with a silica gel column (0.2 m × 1.0 m, 100 to 200 mesh, 1.0 kg), and then eluted with CHCl 3 -MeOH (1% MeOH, 3% MeOH, and 10% MeOH, each 5 L), to obtain 10 fractions. Fr. 4 (5g) was chromatographed on a silica gel column (2.5 × 18 cm, 300 to 400 mesh, 50 g), eluted with CHCl 3 -MeOH (50:1), and further purified by semi-preparative HPLC (45% MeOH) to give compounds 2 (25 mg), 4 (30 mg), and 7 (18 mg). Fr. 5 was separated with a silica column (2.5 × 18 cm, 300 to 400 mesh, 50 g), eluted with CHCl 3 -MeOH (30:1), and then purified by semi-preparative HPLC (50% MeOH) to yield compounds 1 (2 mg), 3 (7 mg), 5 (7 mg) and 6 (7 mg). The purities of compounds 1-7 were 95%, as determined by TLC and HPLC.
Cytotoxicity assay: Cytotoxicity of compound 1 against HL-60 (human premyelocytic leukemia) cells and A549 (human lung adenocarcinoma) was measured by MTT and SRB methods, respectively. Adriamycin was used as the positive control (IC50 0.16 μM against HL-60, IC50 0.38 μM against A549). Cells were plated in 96-well plates 24 h before treatment and continuously exposed to different concentrations of compounds for 72 h; inhibition rates of cell proliferation were further determined [9] . 
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